GTx Inc. shares surged nearly 30% in Monday trade after the company reported additional results from a phase 2 trial of its drug for postmenopausal women with stress urinary incontinence. The latest data suggest that the drug, enobosarm, could also work for women with urge incontinence and thus have “a possible treatment effect for women with mixed incontinence,” the company said. A post hoc analysis of a subset of trial patients consisting of women with both types of incontinence — which means the analysis wasn’t specified before seeing the data — found that use of enobosarm reduced average urge incontinence episodes by about 68%. The phase 2 trial in question enrolled 18 patients total, 11 of which had both types of incontinence. Stress urinary incontinence consists of unintentional urine leakage during activities like coughing, sneezing or exercise, and affects up to 35% of adult U.S. women, according to GTx. Urge incontinence refers to the involuntary loss of urine at the time of a sudden, strong need to urinate, and the two often coexist, the company said. GTx shares have surged nearly 75% over the last three months, compared with a 3.1% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
